Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

NCT01032408 is registered in ClinicalTrials.gov with Chiltern Pesquisa Clinica Ltda as lead sponsor.

NCT NCT01032408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01032408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Lead sponsor
Chiltern Pesquisa Clinica Ltda
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
July 31, 2012
Enrollment
154 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

h1n1 influenza virus, human immunodeficiency virus type 1 (hiv-1) infection